Cardea Bio Acquired by Paragraf

The Serra team is very pleased to announce the acquisition of portfolio company Cardea Bio on May 2, 2023.

In a first for the graphene electronics industry, leading integrated device manufacturer Paragraf is acquiring graphene biosensor market pioneer Cardea Bio to accelerate the mass production of a new generation of devices that will deliver real-time analysis in point-of-need tests in the agritech, healthcare and environmental monitoring spaces.

Cardea is a Serra Capital II and Serra Capital II Follow-On-Fund company, with an initial investment made in April of 2015.

“Joining Paragraf allows us to use the world’s only mass-produced, transfer-free monolayer graphene to manufacture the state-of-the art graphene-based biosensors developed by the Cardea team over the last ten years. We are looking forward to unlocking powerful synergistic effects to advance the broad and growing use of graphene biosensors for the benefit of both people and the planet” said Michael Heltzen, EVP of Strategy at Paragraf USA (former CEO and co-founder of Cardea Bio).

To view the full press release, follow here.